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Advances in tissue engineering 
of the cardiac muscle for myocardial regeneration
Abstract
Tissue engineering is currently at the avant-garden of research and aims to build regenerative alternatives 
in vitro by means of combining a scaffold material, adequate cells and bioactive molecules. It has been 20 
years since the initial description of a tissue engineering construct, but in relation to the management of 
heart disease, these new technologies are not yet fully established, due to the challenges presented by 
their transfer to the clinic. However, advancements are being made into these therapies, and therefore 
it necessary, for example, support to academic laboratories, adequate funding, cooperation between di-
fferent laboratories by coordinating comparable approaches and evidence-based information. Generally, 
scaffold materials such as gelatin, collagen alginate or synthetic polymers and cardiac cells are used to 
reconstitute native tissue-like constructs in vitro. They should have propensity to intgrate and remain 
contractile in vivo. This review aim is to present cardiac tissue engineering strategies for the functional 
recovery of altered cardiac tissue with a focus on different methods of application, neovascularization, 
advances in 3D bioprinting and future perspectives.
Resumen 
La ingeniería de tejidos está actualmente en la vanguardia de la investigación y tiene como objetivo 
construir alternativas regenerativas in vitro mediante la combinación de un material de andamiaje, células 
adecuadas y moléculas bioactivas. Han pasado 20 años desde la primera descripción de una construcción 
de ingeniería tisular, pero en relación con el manejo de las enfermedades cardiacas, estas nuevas 
tecnologías aún no están completamente establecidas, por los desafíos que presenta su traslación a la 
clínica. No obstante, se está progresando con estas terapias y por ello se necesita, por ejemplo, apoyo a 
los laboratorios académicos, financiación adecuada, cooperación entre los distintos laboratorios mediante 
la coordinación de enfoques comparados e información basada en evidencia. Generalmente, se utilizan 
materiales de andamiaje como gelatina, colágeno, alginato o polímeros sintéticos y células cardíacas para 
reconstuir in vitro constructos similares a los tejidos nativos. Estos deben ser propensos a integrarse y 
permanecer contráctiles in vivo. El objetivo de esta revisión es presentar las principales estrategias de 
ingeniería tisular para la recuperación funcional del tejido cardiaco alterado con un enfoque en los distintos 
métodos, la neovascularización, los avances en la bioimpresión 3D y  las perspectivas futuras.
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INTRODUCTION
Myocardial infarction (MI) is the outcome of many cardio-
vascular diseases and heart transplant is actually the only so-
lution for these patients. Althought, stem cell-based therapy 
has emerged as a promising approach for prompting cardiac 
rejuvenation, it still has its limitations in terms of the degree 
of regeneration of the infarcted tissue and the improvement 
of cardiac function (1). A major problem for cell therapy is 
the low level of retention of infused or injected cell products. 
Most studies concur that only few of the transplanted cells 
survive in the hostile environment of the host tissue, and 
even fewer integrate and are retained in the host myocardium 
scar (2). However, transplantation also has its limitations in 
relation to the lower number of donors or the risk of inmune 
rejection of the graft. Faced with the need to overcome the-
se obstacles, strategies have emerged over the years focused 
on restoring complete cardiac function by reconstructing the 
affected tissue by incorporating within scaffolds cells, wich 
provide optimal structural, mechanical and physiological pro-
perties (3). This field of work is called Tissue Engineering (TE), 
wich is a multidisciplinary field that combines the principles of 
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biology, engineering, chemistry, biotechnology and medicine to 
artificially construct biological substitutes in order to repair or re-
generate damaged tissues (4), (Figure 1).
To understand that it is a tissue engineering product we 
have to take into account three components: stem cells, growth 
factors and scaffolds.
As for cell sources, stem cells are the primary source due to 
their ability to proliferate and promote tissue regeneration, relea-
se a wide range of growth factors and modulate the host inmune 
response (5). Once we have the cell type, the behaviour and pro-
liferation should be guide either by manipulating the extracellular 
microenvironment in which the cell is going to develop its activity 
or by genetically manipulating these cells to modify the synthesis 
of the extracellular matrix, inhibit the immune response or alter 
cell proliferation. Regarding the growth factors, the cell response 
derives from the detection of chemical signals or physical stimu-
lus from the extracellular environment, wich will activate molecu-
lar and biological mechanisms responsible for division, migration, 
differentiation, phenotype maintenance or apoptosis. Therefore, 
controlling the concentration, local duration and spatial distribu-
tion of these factors is essential to their utility and efficacy (6). 
Lastly, scaffolds are used as structural support for the new mi-
croenvironment of the biological substitute. They will allow cell 
union, migration and differentiation, as well as they favour an or-
ganisation to facilitate the action of growth factors and molecular 
signals (3). In this regard, hydrogels appear to be the most promi-
sing biomaterials due to their high hydratation, easy tunning for 
recreate extracellular matrix (ECM) properties and biocompatibi-
lity (7). These properties favour a suitable microenvironment for 
cell growth, the incorporation of drugs and the controlled release 
of biologically active agents (8). In order to optimize the physical 
and mechanical properties of hydrogels, nanoparticles acting as 
enhancing materials have also been investigated to incorporate 
into different kinds of natural or synthetic polymer networks to 
prepare nanocomposite hydrogels for TE (7).
Basic research is essential and subsequently, the translation 
of these pre-clinical results into clinical practice plays a crucial 
role. It is necessary the adaptation of the in vitro and in vivo stu-
dies, as well as the biofabrication protocols to a good manufac-
turing practice manufacturing process and the design of an ad-
vanced therapy clinical trial obeying European requirements and 
regulations. In Andalusian there are two successful experience in 
the development and clinical translation of two tissue enginee-
ring products: a novel anterior lamellar artificial cornea (9) and 
artificial autologous human skin (10). Also, recently Traverse et al. 
evaluated the safety and feasibility of a cardiac extracellular ma-
trix hydrogel, in early and late post–myocardial infarction patients 
with left ventricular dysfunction (11).
This review aim is to look over the different strategies, ele-
ments and challenge of cardiac tissue engineering in the scientific 
literature.
SYNTHESIS OF THE REVIEW
This article discusses the scientific literature on scaffolding 
strategies for regenerative therapies by means of tissue enginee-
ring. It will be analyses the cell sources, important methods of 
tissue engineering investigated up to know, essential points of 
neovascularization as well as the 3D bioprinting, and finally the 
future perspectives towards the achievment of transferring this 
strategies to the clinic.
Stem cells
Cells will be responsible for homeostasis and to forming 
the connections between the tissue matrix and the native 
tissue. So it is important to choose the cell type by virtue of 
the objective of the new tissue to be grafted. For this reason, 
stem cells due to their favourable proliferation characteristics, 
tissue regeneration, releasion a wide range of growth factors, 
modulation the host inmune response and serving as feeder 
platform for ex vivo expansion of differenciated cells (5), are 
the most studied to promote tissue engineering processes. 
Stem cells can be allogenic or autologous, but the latter are 
the central focus of research due to the problems of survei-
llance and rejection that still present allogenic cells (3). (Table 
1) shows cells with cardiac regeneration potential.
As we can see, the elaboration of constructs in the labo-
ratory depends mainly on avaibility of viable cells, so viability 
and physiological state maintained in culture must be previusly 
studied in order to be able to use them for clinical purposes. 
Classical methods based on exclusion dyes such as tripan blue 
are used to identify membrane alterations or the metabolic 
state of cells. Other protocols to analyse cell viability include 
a technique using quantitative analytical electron miscroscopy 
by X-ray emission that allows to identify, localize, and quan-
tify elements both at the whole cell and at the intracellular 
level (22,23). Likewise, once the tissue substitute has been 
obtained, it must be analysed and evaluated to guarantee a 
structure similar to that of the native tissue to be replaced and 
that normal functions of the native tissue can be reproduced 
at both in vitro and in vivo levels by the tissue substitutes (24). 
Thus, the evaluation of cell viability is very important and it is 
a basic criteria to ensure therapeutic efficacy of tissues and 
approval as advanced therapy medicament (9,10).
Cardiac Tissue Engineering
Most common cardiovascular diseases can have as a conse-
quence the formation of non-contractile conjunctive scar tissue, 
inflammation of the tissue's microenvironment, calcification of the 
grafts and degradation among others (3). This is why simple repair 
or regeneration focused on the reconstitution of cardiomyocytes 
is ineffective, as the lesion interrupts the organization of cardiac 
tissue and architecture, along with the coordinated interaction of 
cells. It will be important for the repair or regeneration both res-
toration of cell types and scaffold structure to restore electrical and 
mechanical communication between the cardiomyocytes and the 
environment. Therefore, key points of regeneration are the sources 
of new cardiomyocytes, the role of inflamatory and inmune cells, 
extracellular matrix, neovascularization and lymphagenesis (25).
Cardiac tissue engineering objective is to reconstitute the 
contractile tissue of the myocardial muscle in vitro using synthetic 
Figure 1. Tissue engineering procedure. 1. Biopsy of the patient 
to extract cells depending on the tissue to be regenerated; 2. After 
surgical dissection, the isolation of the cells must be performed by 
mechanical fragmentation or by enzymatic digestion, so that they 
can subsequently be cultured in a specific culture medium.; 3. We 
need a stroma where the cells can be immersed and development 
in the same way as in their native tissue. Porous scaffold, cells, 
nutrients and growth factors allow the formation of the tissue in 
the culture medium; 4. Evaluation of cell viability;and 5. Implant.
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or biological matrices and cardiac cells to replace the diseased 
myocardium in vivo. Tissue must restore basic cardiac functions 
as well as functional vascularization (26). In addition to the cell 
type, scaffold and bioactive molecules, consideration should be 
given to the bioreactor where the artificial tissue is grown under 
controlled conditions (3). Thus, the ideal construct should be 
contractile, allowing physiological electrical propagation, me-
chanically robust, but flexible, vascularized or capable of rapid 
vascularization after implantation, non-inmunogenic and with 
good biodegradability (3,27).
Currently researches are addressing different methods of 
tissue engineering: biomimetic scaffolds, hydrogels, decellulari-
zed scaffolds and cell sheets. All of them are trated below.
a) Biomimetic scaffolds
A biomimetic biomaterial can be any scaffolding material 
that mimics the characteristics of the natural ECM. They are ba-
sed on polymers that may be natural, synthetic or biosynthetic 
(26,28). They are interesting for the repair and regeneration of 
tissues due to their biodegradability, mechanical properties or 
high porosity. Porosity is it very important in terms of structure 
functionality because it allows cell infiltration and colonization of 
the extracellular matrix improving cell growth, proliferation and 
migration, as well as efficient cell adhesion and diffusion, tissue 
vascularization and tissue formation. So, scaffolds should allow 
the transport of the nutrients needed to the cell attachment, 
proliferation and differentiation, stimulation of cell-biomaterial 
CELL ADVANTAGES DISADVANTAGES    REF. SOURCE
Fetal CMs Potential integration and regeneration
Ethical issues, limited avaibility and 
immunogenicity. Long-term studies 
revealed massive cell death and 







Improvements in left ventricular function, 
functional status, and quality of life were 
observed in patients treated with UC-MSCs
No severe adverse effects were 
observed, but preliminary results, 
need to be confirmed in larger and 




Pluripotent, It has been demonstrated 
in a non-human primate model  that an 
intramyocardial delivery of  human ESC-
derived CMs gave re-muscularization of the 
infarcted zone   




Preclinical studies with AdSCs have shown 
improvement in ventricular function in 
animal models of MI.  Clinical trials in humans 
showed only modest beneficial effects on 
cardiac function and on myocardial perfusion Low survival 3,17 Autologous
Skeletal 
myoblast
Positive outcomes by reducing infarct size, 
as well as myocardial fibrosis, thwarting 
ventricular remodeling and improving overall 





Increase of the mean global left ventricle 
ejection fraction.
Significant differences among the 
trials. The differences made a reliable 
comparison of the trials’ outcome 
and also the reproducibility. 14,19
Autologous
hiPSCs
In vivo transplantation experiments with 
hPSC-CMs have been showed promising 
effects of heart regeneration, like progressive 
maturation and generate remuscularization of 
infarcted heart
Ventricular arrhythmias observed in 




Cardiosphere-derived cells have been shown 
their ability to promote cardiac regeneration, 
reducing the scar size and thickening the wall 
of the infarcted zone in a clinical trial.
Limited avaibility. The real 
regenerative potential remains 
controversial.
21 Autologous
Table 1. Stem cells types used for cardiac tissue engineering 
 
AdSCs: Adipose stem cells-based; BMD: bone marrow-derived stem cells; ESC-derived Cms: Embryonic-stem-cell-derived 
cardiomyocytes; Fetal Cms: Fetal cardiomyocytes; hiPSCs: human induced pluripotent stem cells; hPSC-CMs: human pluripotent stem 
cells derived cardiomyocytes; LVEF: left ventricular ejection fraction MI: miocardial infartion; UC-MSCs: Umbilical cord Mesenchymal 
Stem Cells (1,3,12-21).
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attachment, growth and migration, mechanical support and a 
controlled degradation rate with no toxicity or inflammation risk 
to the cells (10).
Naturals polymers shows biological properties that better 
fit to the regular microenvironment of tissues, promoting desi-
rable cellular response, biocompatibility and degradability. They 
are derived from biological sources and the most common mate-
rials in cardiac tissue engineering are collagen and gelatin (deri-
ved from mammalian extracellular matrix) and alginate. The use 
of natural materials has been expanded through incorporation 
into co-polymer structures with synthetic biomaterials, such as 
polycapralactone and poly-L-lactic acid, or chitosan for improve-
ment of scaffold or hydrogel properties. As for the synthetic po-
lymers are an attractive alternative to natural materials because 
they have the ability to control the entire synthesis procedure, 
their mechanical properties, topography and structure of the ma-
terial. Consequently, they are preferred for in vivo applications to 
allow for the engineered tissue to integrate and minimize adverse 
host response. The most notable polyesters are FDA-approved 
polycapralactone, poly-L-lactic acid, and poly(lactic-co-glycolic 
acid), which have been applied in many tissue engineering appli-
cations (29). It is essential to use biocompatible and biodegrada-
bility gels in order to avoid both long-term bioreactions and toxic 
inflammatory reactions (30).
Biomimetic scaffold can be used alone as acellular 
scaffolds or in combination with cells (31) and generally must 
be non-inmunogenic, mechanically stable and flexible, allow 
physiological electrical propagation and nutrients to the cells, 
and have biodegradability rate. When combined with cells (Ta-
ble 2) they may improve the retention of transplanted cells 
as well as increase cell survival. Injection of acellular scaffolds 
with or without bioactive molecules aids in structural mecha-
nic support, decrease of fibrosis and ventricular dilation, as 
well as promotes recruitment of native stem cells and angio-
genesis (26,32). Recently, McLaughlin et al. have reported the 
first injectable biomaterials made from recombinant human 
collagens type I (rHCI) and type III (rHCIII), instead of using 
animal-derived components. After pre-clinical performance in 
a well-established mouse model of MI, their results highlight 
the potential for a biomaterial based on human recombinant 
collagen to be used as therapy for the improvement of cardiac 
function post-MI (33).
b) Hydrogels
Hydrogels are the most commonly used polymers in 
tissue engineering and exactly they are the natural extracellu-
lar matrix protein collagen I, mixtures of collagen I and matrigel 
and the blood-clotting material fibrin (32,34,35). The elasticity 
and swelling properties of hydrogels make them desirable for 
injectable purposes and bioprinting applications. Pororsity and 
mechanical properties are also important in terms of biocompa-
tibility and structural similarity to the native ECM (10).
Already in the 90s, Eschenhagen et al. (36) succeeded in 
obtaining three-dimensional heart tissue developing a method 
for cultivating cardiomyocytes in a collagen matrix and allowed 
them to gel between two Velcro-coated glass tubes. This opened 
up the possibility of being able to study in vitro the functional 
consequences of genetic or pharmacological manipulation of car-
diomyocytes under highly controlled conditions.
Some research groups have developed a natural and 
biodegradable hybrid composed by human fibrin and agarose 
type VII, a polysaccharide originating from algae (FAH). It has 
been applicated in the construction of different engineered 
tissues like cornea (37), skin (38), oral mucosa (24) and pe-
ripheral nerve (39) among others, and they have shown that 
the nanostructuration and cross-linking techniques improved 
the biomechanical and structural properties of different bio-
materials.
IN VITRO ENGINEERED TISSUE IN SITU ENGINEERED TISSUE
Gelatin → Alone or with fetal cardiomyocytes
Alginate → With fetal cardiomyocytes
Alginate and matrigel → w/SDF-1, IGF-1 and VEGF w/Neonatal 
CM + SDF-1, IGF-1 and VEGF
Poly(glycolide)/poly(lactide) → With dermal fibroblasts
Collagen type I and matrigel → w/SkM
PTFE, PLA mesh, collagen type I and matrigel → Alone or w/
hBMC-derived MSCs
Collagen type I → Alone or w/BMC, HUCBCs, hBMC CD133+, 
hMSC, hSkM.
PNIPAAM (cell culture dish) → Cell sheet of neonata CM or 
adipose-derived MCSs
Decellularized myocardium/fibrin → w/mesenchymal 
progenitor cells
Pericardium → w/MSCs
Fibrin → Alone or w/hESc-derived Ecs and hESC-derived MSCs
Fibrin → Alone or with BMCs, ASCs, MCSCs, BMMNCs w/bFGF, 
HGF, TGFβ-1
Alginate → Alone, PDGF-BB, IGF-1, HGF 
w/hMSCs or w/Polypyrrole
Collagen → Alone or w/BMC
Hyaluronic acid → Alone
Myocardial and Pericardial matrix → Alone
Alginate → Alone or w/VEGF, PDGF-BB, IGF-1, HGF w/hMSCs or 
w/Polypyrrole
Matrigel → Alone or w/ ESC
Collagen type I and matrigel → Alone or w/neonatal CM
Self-assembling peptides → Alone or w/nenonatal CM, PDGF-BB
Gelatin → Alone or w/bFGF
Calcium hydroxyapatite → Alone
Chitosan → Alone or w/ ESCs, bFGF, neonatal CM w/Polypyrrole
Table 2. Main biomaterials researched for treatment of MI. 
 
ASC: adipose-derived stem cell; bFGF: basic fibroblast growth factor; BMC: bone marrow cell; BMMNC; bone marrow-derived stem cell; 
CM: cardiomyocyte; ESC: embryonic stem cells; HGF: hepatocyte growth factor; HUCBC: human umbilical cord blood mononuclear cell; 
MSC: mesenchymal stem cell; IGF: insulin-like growth factor; PDGF: platelet-derived growth factor; PLA: poly (L-lactic) acid; PNIPAAM: poly 
(N-isopropylacrylamide); PTFE: poly (tetrafluoroethylene); SDF: stromal cell–derived factor; SkM: skeletal myoblast; TGF: transforming 
growth factor; VEGF: vascular endothelial growth factor. (Adapted from ref. 31).
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For cardiac tissue engineering, it is crucial the develop-
ment of electrically conductive hydrogels to achieve the spon-
taneous beating behaviour of the heart, in order to accomplis-
hed the functional regeneration (8,40).
Advances in the science and applications of hydrogel sys-
tems have led to develop 'smart hydrogels', which are polymeric 
scaffolds with tunable properties. They can be triggered by cer-
tain stimulus such as temperature, electric and magnetic fields, 
light, pH, ions, and specific molecular recognition events such as 
glucose. These polymers can exhibit dramatic changes in their 
swelling behavior, sol-gel transition, network structure, permea-
bility, or mechanical strength in response to changes in the pH, 
ionic strength, or temperature, as an example (41).
Newly, there are some contributions about hydrogels. 
First one, shows up an injectable nanocomposite hydrogel, 
which could be potential for vascularization and tissue re-
pair aplicattions. It has been developed with chitosan, gelatin, 
β-glycerphosphate and Arg-Gly-Asp (RGD) peptide and loaded 
with stromal cell-derived factor-1 and vascular endothelial 
growth factor (VEGF) nanoparticles to simulate the natural na-
noparticles in the extracellular matrix to promote angiogenesis 
(42). Secondly, an injectable human amniotic membrane (hAM) 
matrix (43). And, lastly is about the first-in-man clinical trial per-
formed with an extracellular matrix hydrogel derived from dece-
llularized porcine myocardium (Ventrigel), in post–MI patients. 
After preclinical studies showing biocompatibility, hemocompa-
tibility, and lack of arrhythmias, a multicenter trial was develo-
ped to evaluate the safety, feasibility, and preliminary efficacy 
of percutaneous transendocardial delivery of VentriGel in early 
and late MI patients with left ventricular dysfunction (11).
c) Decellularized scaffolds
Decellularized extracellular matrices (dECM) processed 
in vitro could be promising biomaterials for cardiovascular tis-
sue regeneration as it has the potential to overcome the need 
to artificially recreate the conditions from ECM deposition 
(35). They most effectively captures the complex array of pro-
teins, glycosaminoglycans, proteoglycans, and many other ma-
trix components that are found in native tissue, providing ideal 
cues for regeneration and repair of damaged myocardium. In 
addition, dECM can be used either as solid scaffolds that man-
tain the native matrix structure, or as soluble materials that 
can form injectable hydrogels for tissue repair and regenera-
tion (44). For decellularization and subsequent recellulariza-
tion are required a scaffolding organ; a detergent, osmolar or 
enzymatic solution to remove native cell material; stem cells 
for repopulation; and a culture environment, or bioreactor, to 
promote adhesion, growth and integration of new cells (3). 
Generally, decellularization performed by perfusion with SDS 
or Triton X-100 has been done successful in small animal or-
gans and whole organs. This procedure wipes out almost com-
pletely cells from the tissue but leaves connective tissue archi-
tecture of blood vessels intact and most of the components of 
the extracellular fibrillar and non-fibrillar matrix, so it allows 
perfusing of the remaining matrix (44, 45). For cardiovascular 
treatment dECM materials have been limited to repair or re-
placement of heart valves, large vasculature, and congenital 
heart defects using patches and valves (PhotoFix, CryoValve), 
pericardial patches (SJM and Tutopatch) and injectable cellular 
ECM hydrogels with soluble ECM (Ventrigel) (44).
Recently, it have been developed two engineered car-
diac grafts based on decellularized scaffolds from myocardial 
and pericardial tissues. They were repopulated with adipose 
tissue mesenchymal stem cells. It was observed that decellu-
larized scaffolds maintained structural integrity of the native 
matrix fibrils (Figure 2A,B,G,H) and type-I and type-III colla-
gens, were properly marked, indicating preservation of matrix 
protein components (Figure 2J,K). After recellularization it 
was confirmed the capability to recruit cells (Figure 2C,I,F,L). 
The mechanical properties of cardiac tissue were evalua-
ted and no significant changes were found when comparing 
data along the different recellularization steps. Comparative 
analysis of the generated acellular myocardial and pericardial 
tissues revealed they shared 40% of the matrisome proteins, 
wich are involved in cellular processes such as maintaining 
the ECM structure and modulating cell differentiation (co-
llagens type-I, -III, -IV, -V, -VI), cell adhesion (laminin family 
and heparan sulfate), or survival and differentiation proces-
ses (fibronectin). Immunohistological analysis showed co-
rrect adhesion of the implanted graft with myocardium and 
hystological analysis showed functional blood vessels con-
nected to host vascularization in all scaffolds of the experi-
mental groups. Both engineered cardiac grafts were further 
evaluated in pre-clinical MI swine models and demonstrated 
biocompability and efficacy, improving ventricular function, 
as well as integration with the underlying myocardium and 
signs of neovascularization and nerve sprouting (46). At this 
moment, it is going under an interventional clinical trial (Pe-
riCord) and it is based on a decellularized pericardial matrix 
with mesenchymal stem cells that carries them directly over 
myocardial infarction.
d) Cell sheets
This technique is based on the construction of cell sheets 
without scaffolding using specialized temperature-responsive 
polymer surfaces, wich allow to binding of cells, and the dea-
tachment of the cultured cells as an intact layer without al-
tering the deposited ECM (2,34). In that respect, previously 
Inui & Sekine et al. showed up that cocultivation with vas-
cular endothelial cells (Figure 3A), treatment with vascular 
endothelial growth factor (VEFG) and in vitro vascularization 
bioreactors may favour the stacking of three-layers laminae 
in several stages. Recently they have been developed a new 
method involved the layering of cardiac cell sheets derived 
from human induced pluripotent stem cells cocultured with 
endothelial cells and fibroblasts on a vascular bed derived 
from porcine small intestinal tissue (Figure 3B,C). They succe-
eded in engineering spontaneously beating 3D cardiac tissue 
Figure 2. Internal structure and protein composition of the 
cardiac scaffolds. SEM images of the (A) native myocardium, 
(G) native pericardium, (B) decellularized myocardial scaffold 
and (H) decellularized pericardial scaffolds,  showing the 
intrinsical organization and spatial three-dimensional 
distribution of the native matrix fibrils. Native myocardium 
and decellularized myocardial scaffolds, respectively (D,E) 
and (J,K) native pericardium and decellularized pericardial 
scaffolds showing immunostaining for matrix proteins, type-I 
(green) and type-III (red) collagens and cardiac troponin I, 
cTnI (white). (C) recellularized myocardial and (I) pericardial 
scaffolds,  showing the presence of cells detected using SEM 
and  (F,L) displaying immunostaining for col-I (green) for 
recellularized myocardial and pericardial scaffolds. Nuclei 
were counterstained with DAPI (blue). Scale bars = 50 μm. 
Reproduced from Perea-Gil et al 46 with permission of the 
publisher. Copyright ©  2018, Springer Nature. Creative 
Commons license: http://creativecommons.org/licenses/
by/4.0/.
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in vitro. The bioengineered cardiac tissue was transplanted 
into another pig and observed to beat spontaneously after 
reperfusion with blood, but waiting for immunogenicity, steri-
lity and scalability responses (47).
Neovascularization and Lymphangiogenesis
After a myocardial injury, the vascularization plays a crucial 
rol to allow tissue engineering constructs to survive and grow. It 
is essential to overcome the challenging of neovascularization in 
TE, which aim is similar as much in ischemic disease and in pe-
ripheral vascular disease. Therefore, results in therse areas are 
important for the clinical aplicaction of angiogenesis in tissue 
engineerring. Angiogenesis is te formation of new vessels from 
pre-existing vessels and vasculogenesis is the formation of vessels 
fron endothelial progenitor cells. This two strategies have been 
approached by reserchers to overcome the inadequate vascula-
rization (48,49). The mechanisms of neovascularization are not 
yet well defined, but it has been proposed that the epicardium is 
reactived after the injury and secretes classical angiogenic factors 
(VEGF, CXCL12, C-X-C motif chemokine 12, or SDF-1), fibroblast 
growth factor, and retinoic acid. These factors would promote the 
epithelial-to-mesenchymal transition of epicardium-derived cells 
that invade the underlying myocardium, giving rise to pericytes, 
smooth muscle cells and fibroblasts (25).
On the one hand, strategies for improving local circula-
tion could be induce angiogenesis by manipulating pro-angio-
genic growth factors. Other alternatives have been proposed 
such as combining endothelial cells with tissue-specific cells 
on a scaffold before transplantation to improve the prevascu-
larize of the graft or target site before implantation. On the 
other hand, hypoxia may have certain advantages. Under hy-
poxic conditions carries out its function and regulates gene 
expression of VEGF and stromal cell-derived factor (SCDF-1). 
SCDF-1 binds to the receptor CXCR4 acting as a chemokine and 
attracts stem cells, including circulating endothelial progenitor 
cells, to areas of hypoxia (48).
As far as the lymphatic system, it is important for tissue 
fluid homeostasis and trafficking of inmune cells. It has been 
described above that inflamation can activates regenerative 
pathways and in rodent it has been observed that an induction 
of lymphangiogenesis with with VEGF-C (vascular endothelial 
growth factor C) improves healing, reduces fibrosis, and pre-
serves myocardial function after myocardial infarction (25).
3D Bioprinting
Construction of a vascular organ like heart is still being a 
challenge, as well as the synchronization of synthesized tissue 
constructs with native tissue and execution of spontaneous 
contraction. Recently, once of the most important technolo-
gical advances is 3D bioprinting. This strategy provides an al-
ternative to develop a heterogeneous 3D scaffold with strong 
mechanical strength and with all required characteristics of 
an ideal scaffold for cardiac tissue engineering. There are 
two main categories of 3D printing processes: scaffold-based 
printing and scaffold-free printing. First one, preprinting of 
scaffold and then cell layers printing or simultaneous printing 
of biomaterials and cells. Second one, bioink consists of indi-
vidual cells or tissue spheroids are used for direct printing on 
substrate (50). Noor et al. have demonstrated an approach 
for engineering personalized tissues and organs using non 
supplemented materials as bioinks for 3D bioprinting (Figure 
4). They reported on the potential of 3D bioprinting to engi-
neer vascularized cardiac patches that fully match the anato-
mical structure, the biochemical and cellular components of 
any individual. Furthemore, cellularized hearts with a natural 
architecture were engineered, demonstrating the potential 
for organ replacement or for drug screening in an appropriate 
anatomical structure. However, it is necessary to perform fur-
ther in vitro studies and in vivo implantation experiments in 
animal models (51), and to consider the heterogeneity of the 
polymeric materials selected as bioinks, but also the influence 
the cell material dynamisms in the printing process because the 
shear stress caused during the bioprinting also affects cell viabili-
ty and integrity (8).
Another emerging technology with promising advances 
is organs-on-a-chip (OOAC), which are miniature tissues and 
organs grown in vitro that enable modeling of human physio-
logy and disease. OOAC offer a promising approach to emulate 
human patho/physiology in vitro, drug development, disease 
modeling, and precision medicine (52). Microfluidics devices 
like organ-on-a-chip and lab-on-a-chip could be a potential te-
chnique to observe a real-time effect of biochemical, mechanical, 
and electrical stimulations on new heart tissue constructs to im-
prove tissue functions (50).
Figure 3. Cell-sheet onto a vascular bed . (A) Endothelial 
cells (ECs) cocultured cardiac cell sheets are stacked. Then 
overlaid on a vascular bed in vitro and after appropriate 
perfusion using a bioreactor, the cocultured ECs formed new 
blood vessels and connected with the blood vessels that 
originated from the vascular bed. (B) Vascular bed created 
from porcine small intestine. Histological analysis with Azan 
trichrome staining revealed the adequate resection of the 
mucosa and the preservation of the extracellular matrix and 
small vessels (before vessels perfusion) without damage to 
the tissue. (C) Hematoxylin-eosin staining confirmed that the 
tissue had not been damaged by mucosal resection and cell 
nuclei were present throughout the remaining tissue (before 
perfusion culture). (B) and (C) reproduced from Inui et al 47 
with permission. Copyright © 2019, The Japanese Society 
for Regenerative Medicine. https://creativecommons.org/
licenses/by-nc-nd/4.0/
Figure 4. Personalized 3D bioprinting. It is extracted an 
omentum tissue from the patient. Cells are separated from the 
matrix, reprogrammed to become pluripotent and differenciated 
to cardiomyocytes and endothelial cells. The matrix is processed 
into a personalized hydrogel. Then, cells and personalized 
hydrogel are encapsulated to generate bioinks in order to 
printed them to engineer vascularized patches and complex 
cellularized structures (51).
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In spite of these advances, it is needed in the future to in-
tegrate all conventional 3D tissue engineering techniques (3D 
scaffold fabrication techniques, hydrogels, nanofibers, and dece-
llularization) with modern scaffold-free 3D bioprinting to achieve 
the most realistic functional heart (50).
OUTLOOK AND CONCLUSIONS
Tissue engineering is essential for the construction of arti-
ficial tissues, disease modeling and drug screening. Its objective 
was traditionally and it still is to provide in vitro functional tissues 
by mimicking the native ECM composition and structure.
Main current challenges are the inconsistency of the ro-
dents hearts studies due to the substantial differences in the car-
diac physiology of these with to human heart. Thus, testing has to 
be performed in animals with a cardiac physiology closer to that 
of humans and it is necessary improved the TE strategies to in-
crease cell retention. (34,53). Actually, the use of tissue-enginee-
red constructs for myocardial regeneration is still in the preclinical 
phase, with some exceptions (reflect on ref. 53).
To date, there are several important points. Firstly, cardiac 
tissue engineering offers teorical advantages over cell therapy 
such as better cell retention or a controlled environment, and 
myocardial regeneration must be considered as a global and ba-
lanced process involving both cells and other cardiac structures. 
Electromechanical cellular coupling within the matrix is funda-
mental to restore cardiac function and the vascularization of the 
artificial tissue will determine its own viabilty and integration 
with the host tissue. The benefits of an acellular injectable bio-
materials are being disscused because they suggest promoting 
angiogenesis in preclinical models and have been demostrated 
to prevent adverse remodeling after myocardial infarction, but 
nevertheless some randomized trials with natural biomaterial 
alginate have failed to provide functional benefits. It is impor-
tant to optimize the selection of appropriate biomaterials and 
processes for further studies in vitro and in vivo focused on how 
to achieve an adequate in vitro vascularization and perfusion of 
engineered constructs for generation large tissue construct to 
replace a scar and to create appropriate models to test safety 
and efficacy of human heart engineered tissue (25).
Secondly, as for the challenges presented by hydrogels, it 
has been improved theirs physical-chemical properties such as 
stiffness, porosity, degradability and cell adhesion properties 
among others, to fabricate complex biomimetic architectures 
for specific tissue regeneration. Combining these hydrogels 
with stem cell technologies and optimized physical-chemical 
cues will further allow for the mimicking of the dynamic rege-
neration-stage specific microenvironment (8,42,43). And fina-
lly, pure decellularized extracellular matrices (dECM) materials 
have been shown to improve cardiac functionality in a large 
animal models post-MI or ischemia, with improved angioge-
nesis, reduction in inflammatory response, increased progeni-
tor cell recruitment, and stimulation of positive remodeling. So, 
combined pure dECM materials with cells, additional biomate-
rials, or paracrine factors suggest an approach based on combi-
national therapies (35,46).
In conclusion, the complexity of the biological processes 
in regeneration are evident and some quentions remain hidden. 
Although cardiac tissue engineering is not one of the most active 
areas of research compared to bone tissue engineering or skin 
tissue engineering, it has been made considerable progresses in 
this field with satisfactory results in some clinical studies showing 
many benefits. Hydrogel-based matrices seem like interesting 
biomaterials for engineered tissue scaffolds due to their simila-
rity to native ECM and advanced nanotechnologies have enabled 
to improve the properties of hydrogels. Also, dECM has received 
a considerable interest because of it preserves the native tissue 
composition, and 3D bioprintings human tissues of disease may 
improve the efficacy of regenerative medicine strategies and en-
hance the translation to the clinic of promising approaches. Re-
garding the transfer to the clinic, since the development of these 
tissue engineering products is mainly carried out at universities 
and public hospitals, the support of non-comercial clinical trials 
and multidisciplinary groups is essential to facilitate tranferring 
basic research to the clinic.
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